Nasdaq atai.

May 25, 2023 · ATAI Life Sciences (NASDAQ:ATAI) is a renowned global biopharmaceutical company specializing in developing innovative treatments for mental health disorders. The company has recently garnered ... The Company’s $209M cash position and committed term loan funding is expected to fund operations into 1H 2026. NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ ...1Y 5Y No 1Y chart data available About ATAI ATAI Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in acquiring, incubating, and …8. Atai Life Sciences N.V. (NASDAQ:ATAI) Number of Hedge Fund Holders: 10 Cathie Wood’s hedge fund dumped a whopping 5.6 million shares of Germany-based Atai Life Sciences N.V. (NASDAQ:ATAI) in ...

How much insider buying is happening at Atai Life Sciences? Insiders have purchased a total of 1,618,685 ATAI shares in the last 24 months for a total of $3,116,715.96 bought.Atai Life Sciences (Nasdaq: ATAI) Always at the top of the list of psychedelics companies on the move, Atai Life Sciences launched a Phase 1 study of an MDMA derivative focusing on post-traumatic stress disorder in September.atai ended the third quarter of 2022 with a cash position of $304.1 million, which combined with committed funding from the Hercules loan facility, is anticipated to provide cash runway into 2025 ...

Through its subsidiary Perception Neuroscience, atai Life Sciences N.V. (NASDAQ:ATAI) recently released an update on another platform for treatment resistant depression (TRD) ...

Sep 21, 2021 · NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- DemeRx IB, Inc. ("DemeRx"), an atai Life Sciences (Nasdaq: ATAI) ("atai") platform company focused on developing ibogaine for the treatment of opioid ... NEW YORK and BERLIN, Sept. 27, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), which is developing EMP-01, a 3,4-methylenedioxy-methamphetamine (MDMA) derivative for ...Cathie Wood’s hedge fund dumped a whopping 5.6 million shares of Germany-based Atai Life Sciences N.V. (NASDAQ:ATAI) in the first quarter of 2023.“In just four years with Florian as CEO we raised more than $600 million, grew the staff to more than 100, brought eight compounds into clinical-stage trials, and took Atai public on the Nasdaq ...Atai Life Sciences (NASDAQ:ATAI) closed at $1.06, down from prior weeks’ closings at $1.3, $1.28, $1.39 and $1.29. Incannex Healthcare (NASDAQ:IXHL) closed at $0.99, up from prior week’s close ...

A number of companies in the psychedelics space have listed on the Nasdaq this year, including Compass Pathways (NASDAQ:CMPS), MindMed (NASDAQ:MNMD), Atai Life Sciences (NASDAQ:ATAI) and GH ...

Atai Life Sciences N.V. (ATAI) NasdaqGM - NasdaqGM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 1.1000 +0.0100 (+0.92%) At close: 01:00PM EST. 1.1400 +0.04 (+3.64%) After hours: 04:54PM...

The Company’s $209M cash position and committed term loan funding is expected to fund operations into 1H 2026. NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ ...4 days ago ... Atai Life Sciences N.V.'s stock symbol is ATAI and currently trades under NASDAQ. It's current price per share is approximately $1.12. How much ...-5.91%. Nasdaq Biotechnology Ishares ETF. VHT, 0%, -1.78%. Healthcare ETF ... atai Life Sciences B.V. is based in BERLIN. See More. ATAI Related stocks. Symbol ...Atai Life Sciences N.V. (NASDAQ:ATAI) AVROBIO, Inc. (NASDAQ:AVRO) Axsome Therapeutics, Inc. (NASDAQ:AXSM) (communicated in its earnings release a potential delay in approval of its major ...Let’s get straight to it: The psychedelic stock market continues to underperform. Taking a look at our Psychedelic Invest Index, we can see that only two companies that trade for a greater than $50 million market cap were up in the month of November: atai Life Sciences (ATAI) & GH Research (GHRS). Wait, there are...Atai Life Sciences (NASDAQ: ATAI) focuses on therapeutics to treat mental health issues, such as anxiety, depression or addiction. This clinical-stage biopharma company went public in June 2021.

Ticker Symbol: ATAI: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: IPO Price: $15.00: CIK Code: 0001840904: CUSIP Number: N0731H103 ...The Company’s $250M cash position and committed term loan funding is expected to fund operations into 1H 2026. NEW YORK and BERLIN, May 11, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ ...Ticker Symbol: ATAI: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: IPO Price: $15.00: CIK Code: 0001840904: CUSIP Number: N0731H103 ...NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming …atai Life Sciences N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, recently announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day.

“In just four years with Florian as CEO we raised more than $600 million, grew the staff to more than 100, brought eight compounds into clinical-stage trials, and took Atai public on the Nasdaq ...Jan 18, 2022 ... In December, it was announced that atai would be added to the Nasdaq's prestigious biotechnology index. ... Atai Life Sciences Has Been Selected ...

Nov 14, 2023 · NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health ... Nov 14, 2023 · Clinical-stage psychedelics company atai Life Sciences (NASDAQ:ATAI) reported its financial results and corporate updates for the third quarter ended September 30, 2023. In numbers: Cash, cash ... Stock Price & Overview 3.84K followers $1.07 -0.05 ( -4.46%) 4:00 PM 11/21/23 NASDAQ | $USD | Post-Market: $1.11 +0.04 (+3.74%) 7:59 PM Summary Ratings Financials …NASDAQ Health Care/Life Sciences Compare to Open 1.12 Prior Close 1.09 (11/22/23) 1 Day ATAI 0.92% DJIA 0.33% Russell 2K 0.67% Health Care/Life Sciences 0.32% …Analyst's Opinion · Consensus Rating. Atai Life Sciences has received a consensus rating of Buy. · Price Target Upside/Downside. According to analysts' ...atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101. - This two-part phase 1 trial in healthy volunteers was designed to assess the safety, pharmacokinetics ...ATAI Life Sciences N.V. Common Shares (ATAI) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Based on analysts offering 12 month price targets for ATAI in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .Atai Life Sciences (NASDAQ:ATAI) closed at $1.06, down from prior weeks’ closings at $1.3, $1.28, $1.39 and $1.29. Incannex Healthcare (NASDAQ:IXHL) closed at $0.99, up from prior week’s close ...

If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...

atai Life Sciences N.V. (NASDAQ: ATAI), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, recently announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day.

Atai Life Cuts Expenses, Extends Cash Runway. Atai Life Sciences (NASDAQ: ATAI) announced fiscal second-quarter results today for the quarter ending June 30, 2022 with no revenue, but an update on expenses and cash levels. Read more here. Rubicon Organics Sales Rise as Premium Brand Grows.Clinical-stage biopharma company atai Life Sciences (NASDAQ:ATAI) announced the dosing of the first subject in majority-owned subsidiary Perception Neuroscience’s Phase 1 intravenous-to ...Atai Life Sciences (NASDAQ: ATAI) focuses on therapeutics to treat mental health issues, such as anxiety, depression or addiction. This clinical-stage biopharma company went public in June 2021.111.91%. Get the latest ATAI Life Sciences NV (ATAI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment... Oct 2, 2023 · NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October. October 6, 2023. Press Release. Summary Real-Time After-Hours Pre-Market Charts NEWS & ANALYSIS News Press Releases Analyst Research ATAI ATAI REAL TIME ATAI Real-Time Quotes 1D 5D 1M 6M YTD 1Y 5Y MAX Last Five Real-Time...Atai Life Sciences (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company transforming the treatment of mental health disorders. On January 12, ...Short Interest. Many investors believe that rising short interest positions in a stock is a bearish indicator. They use the Days to Cover statistic as a way to judge rising or falling sentiment in ...

About Pre-Market Quotes. Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. NVIDIA Corporation Common Stock. ATAI Life Sciences N ... The fund has raised an initial $35 million in capital and currently holds an active portfolio of 20 companies, including investments in Atai Life Sciences (NASDAQ: ATAI), Reset Pharma, Field Trip ...The Panera Bread Company is a public company that is traded on the NASDAQ stock market. The majority of its shareholders are financial institutions and mutual fund holders. The remaining shares are owned by direct holders of Panera Bread st...NL0015000DX5. ATAI Life Sciences NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headquartered in Berlin, Germany. Show more. Instagram:https://instagram. batt stock pricegrowth fund of america agte stock symbolcommercial real estate online courses NEW YORK and BERLIN, Nov. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor events & healthcare conferences: Financial Times Pharma and Biotech Summit in LondonOctober 6, 2023. NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inau... atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy ... best credit card for active militarybe stocks The Company’s $209M cash position and committed term loan funding is expected to fund operations into 1H 2026. NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ ...Get ATAI Life Sciences BV (ATAI) share price today and stock analysis, price valuation, performance, fundamentals, market cap, shareholding, ... share price of lvmh Topline results are expected in the first half of 2024. NEW YORK and BERLIN, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage ...NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company focused on mental health ...The financial services firm H.C. Wainwright & Co. recently issued a $20 price target on ATAI Life Sciences (ATAI 7.69%) stock. This 12-month price target implies an upside potential of 969% from ...